Next generation of targeted radiotherapy drugs emerging from the clinical pipeline.
Goldman
Bruce
B
D000911:Antibodies, Monoclonal / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary; D002986:Clinical Trials as Topic; D018450:Disease Progression; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D009101:Multiple Myeloma / Q000188:drug therapy; D009369:Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D018358:Neuroendocrine Tumors / Q000188:drug therapy; D009942:Organometallic Compounds / Q000494:pharmacology; D009943:Organophosphorus Compounds / Q000494:pharmacology; D010166:Palliative Care / Q000379:methods*; D011838:Radiation-Sensitizing Agents / Q000009:adverse effects; D019275:Radiopharmaceuticals / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D018000:Receptors, Peptide / Q000187:drug effects*; D013324:Strontium / Q000494:pharmacology
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D009942:Organometallic Compounds; D009943:Organophosphorus Compounds; D011838:Radiation-Sensitizing Agents; D019275:Radiopharmaceuticals; D018000:Receptors, Peptide; C422802:ibritumomab tiuxetan; C061972:samarium Sm-153 lexidronam; C101315:Capromab Pendetide; C025700:strontium chloride; C119496:tositumomab I-131; D013324:Strontium